BioAtla, Inc. (BCAB)

BioAtla, Inc.'s stock price has significantly declined by approximately 91.39% over the past six months. Key events include the announcement of preliminary clinical data from a Phase 1 study of BA3182 in October 2025, third quarter 2025 financial results and flexible financing agreements in November 2025, a $40 million SPV transaction in December 2025, the initiation of a strategic options exploration and restructuring plan in March 2026, fourth quarter and full year 2025 financial results and a share consolidation in March 2026, and a reverse split in April 2026.

BioAtla, Inc.'s products and services are not subject to demand seasonality, as the demand for cancer treatments is driven by disease prevalence and clinical need rather than seasonal factors.

BioAtla, Inc. is a global clinical-stage biotechnology company focused on developing antibody-based therapeutics for solid tumor cancers, utilizing its Conditionally Active Biologic (CAB) platform. The company's pipeline includes Mecbotamab vedotin (BA3011) in Phase 2 trials for multiple solid tumor indications, Ozuriftamab vedotin (BA3021) in Phase 2 studies for treatment-refractory squamous cell carcinoma, Evalstotug (BA3071) in Phase 2 development for multiple solid tumor indications, BA3182 in a Phase 1 dose-escalation study for advanced adenocarcinoma, and BA3361, a CAB-Nectin-4-ADC for treating tumors.

BioAtla, Inc. is headquartered in San Diego, California, and has an operational footprint in Beijing, China, through a contractual relationship with BioDuro-Sundia for preclinical development services.

BioAtla's brand reputation is associated with its innovative Conditionally Active Biologic (CAB) platform technology, which aims to develop safer and more effective cancer therapies. No specific events in the past year have distinctly impacted BioAtla's brand reputation beyond the general progress and challenges inherent to a clinical-stage biotechnology company.

BioAtla, Inc. has a mixed ownership structure including institutional, insider, and retail investors. Institutional investors hold approximately 13.93% to 17.75% of the stock, insiders own around 5.44% to 30.76%, and retail investors hold a significant portion ranging from 46.82% to 77.46%. Major institutional owners include Acorn Capital Advisors, Llc and Vanguard Group Inc. Significant individual insider owners include Carolyn Anderson Short and Jay M. Phd Short.